Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Switzerland

European Innovation Council · Running

VANTAGE Vascularized Next-Generation Tumor-on-Chip for ADC Global Evaluation

Coordinator
Universitaet Bern, Switzerland
Runs
1 September 2026 to 31 May 2027
Status
Running
EU funding
€300k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
101327116

What the project is doing

In the project's own words, from its summary on CORDIS.

Objectives: The project aims to industrialize a human vascularized tumor-on-chip (VANTAGE) to bridge the ""predictive gap"" in Antibody-Drug Conjugate (ADC) development. Primary goals include: (1) Quantifying the ""total spectrum"" of ADC efficacy, from primary tumor regression to the inhibition of micrometastatic seeds

Topics

Who is involved

OrganisationCityCountryRole
Universitaet BernBernSwitzerlandCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI